Savara Inc
SVRANasdaq
$5.52
0.0%Jul 17 close · end-of-day
Price
1Y↑ +139.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4B
Enterprise Value
$1.2B
P/E
—
P/S
—
P/B
7.9
EV/EBITDA
—
PEG
—
FCF Yield
-7.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$129.5M
Free Cash Flow (TTM)
-$107.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-73.6%
ROIC
-3177.6%
Debt / Equity
0.2
Net Cash
$172.7M
Return 1Y
+135.9%
Company profile
Savara Inc. focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor. The company is headquartered in Austin, Texas.
- CEO
- Matthew Pauls
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Texas
- Website
- savarapharma.com
Earnings
SVRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.15↑ +25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $257,000.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$49.3M | -$41.5M | -$38.8M | -$60.0M | -$103.2M | -$123.5M |
| Net income | -$49.6M | -$43.0M | -$38.1M | -$54.7M | -$95.9M | -$118.8M |
| Diluted EPS | — | -$0.32 | -$0.25 | -$0.33 | -$0.48 | -$0.53 |
| Operating cash flow | -$39.8M | -$40.1M | -$34.6M | -$51.1M | -$89.1M | -$101.0M |
| Free cash flow | -$39.9M | -$40.1M | -$34.6M | -$51.4M | -$89.1M | -$101.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -19182.9% | — | — | — | — | — |
| Net margin | -19305.4% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$23.2M | -$26.4M | -$31.2M | -$28.4M | -$31.4M | -$30.3M | -$33.4M | -$39.0M |
| Net income | -$22.2M | -$24.2M | -$29.0M | -$26.6M | -$30.4M | -$29.6M | -$32.2M | -$37.3M |
| Diluted EPS | -$0.12 | -$0.11 | -$0.14 | -$0.12 | -$0.14 | -$0.14 | -$0.13 | -$0.15 |
| Operating cash flow | -$22.5M | -$22.7M | -$23.3M | -$27.2M | -$26.3M | -$22.5M | -$25.1M | -$33.0M |
| Free cash flow | -$22.5M | -$22.7M | -$23.3M | -$27.2M | -$26.3M | -$22.5M | -$25.1M | -$33.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 27, 2026
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.